Dyslipidemias and chronic kidney disease: a focus on pathogenesis and treatment

Q Medicine

Clinical Lipidology Pub Date : 2014-12-01 DOI:10.2217/clp.14.45

S. Vuono, M. Ricci, M. Mannarino, G. Lupattelli

引用次数: 3

Abstract

Abstract Chronic kidney disease (CKD), dyslipidemias and cardiovascular risk are related conditions. CKD is associated with an increased risk of total and cardiovascular mortality. Atherosclerosis can lead to chronic renal failure and at the same time CKD is considered an independent cardiovascular risk factor. The main types of dyslipidemia secondary to nephropathies are dyslipidemia of nephrotic syndrome and dyslipidemia of advanced CKD. Patients with CKD are considered in the highest CV risk category; thus, lipid profile should be evaluated since the first stages of CKD. This review focuses on the current knowledge on the relationship between CKD and cardiovascular diseases, on the pathogenesis of the dyslipidemias secondary to nephropathies and on the main therapeutic options used to treat these dyslipidemias.

查看原文本刊更多论文

血脂异常和慢性肾脏疾病:发病机制和治疗的焦点

慢性肾脏疾病(CKD)、血脂异常和心血管风险是相关的疾病。CKD与总死亡率和心血管死亡率增加相关。动脉粥样硬化可导致慢性肾功能衰竭，同时CKD被认为是一个独立的心血管危险因素。继发于肾病的血脂异常主要有肾病综合征的血脂异常和晚期CKD的血脂异常。CKD患者被认为是心血管风险最高的一类;因此，从CKD的第一阶段就应该评估血脂。本文综述了CKD与心血管疾病之间的关系、继发于肾病的血脂异常的发病机制以及治疗这些血脂异常的主要治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.